Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

176 results about "Intestinal motility" patented technology

There are two types of intestinal motility – peristalsis and segmentation. This motility is brought about by the contraction of smooth muscles in the gastrointestinal tract which mix the luminal contents with various secretions (segmentation) and move contents through the digestive tract from the mouth to the anus (peristalsis).

Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth

InactiveUS6861053B1Eradicate small intestinal bacterial overgrowthSymptoms improvedAntibacterial agentsOrganic active ingredientsBacteroidesAutoimmune responses
Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit / hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit / hyperactivity disorder, autoimmune diseases, or Crohn's disease.
Owner:CEDARS SINAI MEDICAL CENT

Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV (“DPP-IV”), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes, metabolic syndrome (syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.
Owner:PFIZER INC

Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.
Owner:PFIZER INC

Dipeptidyl peptidase IV inhibiting fluorinated cyclic amides

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.
Owner:PFIZER INC

System and method for displaying motility events in an in vivo image stream

ActiveUS20150016700A1Easy to analyzeDiagnosing intestinal motility disordersImage enhancementImage analysisStream captureMotility
A system and method may analyse and display intestinal motility events, based on an image stream captured by an in vivo imaging device. According to some embodiments, the system includes a storage unit to store image frames from the image stream, a processor to select a strip of pixels from a plurality of image frames of the image stream and to align the selected strips adjacently to form a motility events bar, and a visual display unit for displaying the motility events bar to a user.
Owner:GIVEN IMAGING LTD

Polyethylene Glycol Linked Glp-1 Compounds

The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and / or intestinal motility and inhibiting gastric and / or intestinal emptying, or inhibiting food intake.
Owner:ELI LILLY & CO

Polyethylene glycol linked GLP-1 compounds

The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and / or intestinal motility and inhibiting gastric and / or intestinal emptying, or inhibiting food intake.
Owner:ELI LILLY & CO

Compounds useful as motilin agonists and method

A method is provided for treating disorders of gastrointestinal motility which include the steps of administering to a patient in need of treatment of a compound having the structure or a pharmaceutically acceptable salt thereof, a prodrug ester thereof, and all stereoisomers thereof, wherein R1 is selected from alkyl, aryl, cycloalkyl, alkenyl, alkynyl, arylalkyl, heteroaryl, heteroarylalkyl or heterocycloalkyl; Z is selected from —CON(R4)R4a, —SO2N(R4)R4a, —CN, and R4 and R4a are the same or different and are independently selected from hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl or R4 and R4a can be joined together to form a heterocycle; R4b is selected from hydrogen, halogen, hydroxyl, CN, OCF3, CF3, CONH2, SONH2, SO2CH3, NHCOCH3 or NHCO2CH3; and Q is a substituted bicyclic heterocycle. New compounds for use in treating disorders of gastrointestinal motility are also provided.
Owner:BRISTOL MYERS SQUIBB CO

Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.
Owner:PFIZER INC

Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth

InactiveUS20050008652A1Eradicate small intestinal bacterial overgrowthSymptoms improvedBiocideAntipyreticAutoimmune conditionAutoimmune disease
Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit / hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit / hyperactivity disorder, autoimmune diseases, or Crohn's disease.
Owner:CEDARS SINAI MEDICAL CENT

Device for measuring and method for analysing gastrointestinal motility

InactiveUS20100222670A1Stimulate motilityQuantify digestive tube motilityEndoscopesEndoradiosondesMotilityIntestinal motility
The invention relates to a device for measuring the intestinal motility, that comprises a solid marker intended for travelling along the entire digestive system of a living being, or a portion thereof, a detector including means for detecting the position and the orientation of the marker, means for measuring the intestinal motility connected to the detector, wherein the marker and the detector includes transmission means and reception means for transmitting and receiving electromagnetic signals that ensure a bi-directional communication between the marker and the detector. The invention also relates to the use of the above-mentioned device.
Owner:MOTILIS MEDICA

Solid pharmaceutical composition containing a combination of an intestinal motility regulating agent and an antiflatulent

This invention relates to a solid pharmaceutical composition that include a regulating agent of digestive and / or intestinal motility which has an agonist effect on peripheral μ, δ and κ opiate receptors; and an antiflatulent for the treatment and regulation of intestinal motility and flatulence in mammals. More in particularly, the pharmaceutical composition includes: (a) at least a regulating agent of intestinal motility such as trimebutine; (b) at least an antiflatulent such as simethicone; (c) at least a flowability promoter; (d) one or more lubricant; (e) at least an extender / diluent; (f) at least a disintegrant; and, (g) at least a binder.
Owner:PROCAPS

Capsule for detection of gastrointestinal motility and method for preparing teh same

A capsule for detection of gastrointestinal motility and a method for preparing such a capsule is provided. The capsule comprises a capsule enclosure and a preset quantity of radiopaque markers filled in the capsule. The radiopaque markers further comprise a solid X-ray contrast agent, a medical plastic with a density of at most at 1.4 g / cm3 and an auxiliary agent.
Owner:ANKON MEDICAL TECH (SHANGHAI) CO LTD

Glp-1 analog fusion protein formulations

The invention provides a stable solution formulation comprising a GLP-1-Fc fusion at a pH between about pH 6 and about pH 8.5. analogs fused to specific IgG4-Fc derivatives. These formulations provide unexpected and considerably greater chemical stability than when compared to GLP-1 -Fc fusions at a pH outside the described ranges. The formulations comprising a GLP-1-Fc fusion are useful in treating diabetes, obesity, initable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and / or intestinal motility and inhibiting gastric and / or intestinal emptying, or inhibiting food intake.
Owner:ELI LILLY & CO

Uses of human Zven proteins and polynucleotides

The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.
Owner:ZYMOGENETICS INC

Use of human Zven proteins and polynucleotides

The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.
Owner:ZYMOGENETICS INC

Method for modulating the enteric nervous system to treat a disorder

Non-invasive and / or natural orifice procedures, apparatus and methods for modulating the enteric nervous system using one or more energy modalities. A system may include a probe for insertion into a natural orifice (e.g., nasogastrically, orogastrically, nasojejunally) with or without a tube to therapeutically apply energy to modulate one or more portions of the enteric nervous system. The methods described herein may provide energy to stimulate the enteric nervous system to treat disorders such as irritable bowel syndrome, constipation, depression, anxiety and / or to enhance gastric motility, intestinal motility or other neurological responses.
Owner:LEVINE ANDY H

Smallanthus sonchifolius fruit extract and extracting method and application

The invention relates to a yacon fruit extract (Smallanthus sonchifolius fruit extract) and extraction method and application thereof. The extraction method comprises the following steps: (1) harvesting yacon fruits, washing or peeling, mixing with a protective agent at a ratio of 100:(1-10), blending, filtering, washing the filter cake with the protective agent for 2-3 times, and mixing the filtrates; (2) concentrating or drying the mixed filtrate and drying the filter cake; (3) dispersing dried filter cake in concentrated filtrate or dried product of filtrate, to obtain yacon fruit extract. The protective agent may be an acidic solution, a salt solution or a mixture thereof, or an inert gas. The yacon fruit extract has function of improving gastrointestinal functions, that is, function of reliving constipation. The fructooligosaccharide of yacon fruit extract is not absorbed by human body and has effects of cleaning blood, reducing blood lipid level and preventing hypercholesterolemia and diabetes. The yacon fruit extract can promote intestinal motility, reduce food intake and fat intake, promote defecation, reduce the absorption accumulation of lipids, promote lipid metabolism, and reduce weight gain.
Owner:KUNMING UNIV OF SCI & TECH

Fiber type protein meal replacement powder and preparation method thereof

The invention provides fiber type protein meal replacement powder. The fiber type protein meal replacement powder comprises the following components in parts by weight: 5-20 parts of wheat seedling powder, 23-40 parts of functional powdered sugar, 15-25 parts of comprehensive fruit powder, 20-30 parts of whey protein, 3-10 parts of resistance dextrin, 3-10 parts of konjac gum and 3-15 parts of comprehensive cereal vegetable powder. The invention further provides a preparation method of the fiber type protein meal replacement powder. The fiber type protein meal replacement powder is good in solubility, uniform, stable and fine and smooth in mouth feel, has high satiety, is suitable for being used as weight-reducing meal replacement powder, can meet requirements of human bodies for nutrition, can adjust microenvironment of the human bodies, can improve the gastrointestinal motility, and is a healthy food which is suitable for crowds being busy in ordinary life, lack of movement and need weight reduction to eat.
Owner:江苏苏中健康产业有限公司

Mono modified exendin with polyethylene glycol or its derivatives and uses thereof

Disclosed herein are exendin singly modified with polyethylene glycole or a derivative thereof, a method for the preparation of the same, and uses thereof. Exendin modified at lysine (27) with polyethylene glycol shows biological activity similar to that of natural exendin, but is improved in half life. In addition, the modification position and the number of PEG or its derivative are restricted so as to minimize the side effects caused by a variety of combinations of such factors. The exendin is useful in the prevention and treatment of diseases caused by the over-secretion of insulin, or diseases caused due to a decrease in plasma glucose level, the inhibition of gastric or intestinal motility, the promotion of satiety, or the inhibition of food intake, especially diabetes, obesity and irritable colon syndrome.
Owner:D&D PHARMATECH INC

Method of creating zebra fish peristalsis model and screening prokinetic medicaments

The invention belongs to the field of drug screening and particularly relates to a method of creating a zebra fish peristalsis model and screening prokinetic medicaments. The method comprises the following steps of: (1) selecting the zebra fish; (2) inducing the model and treating the compound; (3) quantitatively analyzing through a fluorescence microscope. A fluorescent dye is applied in the invention for the first time to research the gastrointestinal peristalsis conditions, the new research method is a great complement for the existing research models, and the peristalsis model has important value in high throughput screening of the prokinetic compounds due to the maneuverability, non-invasion, simplicity and quickness.
Owner:HANGZHOU HUANTE BIOLOGICAL TECH CO LTD

Methods and compositions for non-invasive, dynamic imaging of intestinal motility

Described are methods and composition for use in non-invasive imaging of intestinal structure and function. These methods can be used to identify, diagnose, assess, monitor and direct therapies for gastrointestinal diseases and disorders. Embodiments of the methods utilize highly sensitive optical imaging and fluorescent spectroscopy techniques to track or monitor packets of organic dye excreted in bile into the intestinal tract to provide quantitative information regarding intestinal propulsion and function.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Traditional Chinese medicinal composition for treating gastrointestinal tract and preparation thereof

The invention relates to a traditional Chinese medicinal composition for treating gastrointestinal tract, in particular to a medicinal composition for treating gastrointestinal tract diseases such as acute and chronic gastritis, enteritis, gastric ulcer, superficial gastritis, gastric acid, gastrectasia, indigestion and the like. The invention also relates to a preparation of the medicinal composition. The traditional Chinese medicinal composition for treating gastrointestinal tract comprises the medicaments in percentage by weight: 10-25 parts of red ginseng, 10-23 parts of poria, 8-20 parts of bighead atractylodes rhizome, 10-25 parts of rhizoma ligustici wallichii, 10-25 parts of rhizoma atractylodis, 10-25 parts of cyperus rotundus, 10-25 parts of medicated leaven, 10-25 parts of gardenia, 10-23 parts of betelnut, 8-20 parts of radix aucklandiae, 5-15 parts of liquorice, 5-8 parts of malt and 10-25 parts of hawthorn. The medicinal composition for treating the gastrointestinal tract is orally taken and has the efficacies of regulating the flow of qi, comforting the stomach, diminishing inflammation, killing pain, repairing gastrointestinal mucosa and ulceration, enhancing gastrointestinal motility, adjusting gastric acid secretion, promoting digestive absorption and the like.
Owner:王志海

Methods of decreasing intestinal motility

InactiveUS20050192270A1BiocideDigestive systemFunctional bloatingFunctional diarrhea
The invention relates to a method of decreasing intestinal motility in a subject in need of treatment. The method comprises administering to the subject a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of decreasing intestinal motility in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone. In certain embodiments, the subject is a subject with a functional bowel disorder, such as IBS, functional abdominal bloating, or functional diarrhea.
Owner:EDUSA PHARMA

Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto

Novel processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto. The compounds prepared by the present processes may be useful, for example, as antagonists to the mu, kappa and delta opioid receptors, and thereby may be useful in the treatment of gastrointestinal motility disorders, and in preventing peripheral opiate induced side effects. The present processes may offer improved yields, purity, ease of preparation and / or isolation of intermediates and final product, and more industrially useful reaction conditions and workability.
Owner:MERCK SHARP & DOHME LLC

Method for preparing prucalopride

The invention belongs to the field of medicinal chemistry, and in particular relates to a preparation method of prucalopride. Prucalopride succinate is a 5-HT4 receptor stimulant with high selectivity and specificity, and is a novel intestinal motility drug. The drug has the characteristics of high selectivity, rapid onset and less untoward effect, and has wide clinical application prospect in the field of constipation treatment. The invention provides a new method for compounding prucalopride, wherein 4-nitro-5-chlor-2,3-dihydrobenzofuran-7-methanoic acid and 1-(3-methoxypropyl)-4-piperidinamine are employed as initial materials to prepare prucalopride; and the preparation method is simple and convenient to operate, less in side reaction, high in yield, mild in reaction condition and convenient for large-scale industrial production.
Owner:BEIJING VENTUREPHARM BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products